Regeneron Pharmaceuticals

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$3,720,700
$3,547,100
$3,145,000
$3,434,300
Gross Profit
3,107,900
2,946,200
2,597,100
2,917,300
EBITDA
1,628,500
1,214,200
872,600
1,115,900
EBIT
1,506,800
1,093,500
758,500
1,002,900
Net Income
1,340,600
1,432,300
722,000
1,159,600
Net Change In Cash
3,720,700
3,547,100
3,145,000
3,434,300
Free Cash Flow
1,107,600
143,100
1,350,700
776,200
Cash
2,011,800
1,928,200
2,602,000
2,730,000
Basic Shares
116,200
115,400
115,100
113,800

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$13,117,200
$12,172,900
$16,071,700
$8,497,100
Gross Profit
12,233,500
10,612,500
13,634,200
7,377,200
EBITDA
4,047,100
5,335,400
9,281,000
3,900,500
EBIT
4,047,100
4,994,000
8,994,800
3,664,600
Net Income
3,953,600
4,338,400
8,075,300
3,513,200
Net Change In Cash
13,117,200
12,172,900
16,071,700
8,497,100
Cost of Revenue
221,300
690,800
577,000
Free Cash Flow
3,667,600
4,424,800
6,529,400
2,003,500
Cash
2,730,000
3,105,900
2,885,600
2,193,700
Basic Shares
113,700
113,500
112,200
115,100

Earnings Calls

Quarter EPS
2024-09-30
$12.46
2024-06-30
$11.56
2024-03-31
$9.55
2023-12-31
$11.86